
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
FDA’s Center for Biologics Evaluation and Research is planning on publishing nine specific guidance documents on gene therapies in 2020.
FDA’s Center for Biologics Evaluation and Research (CBER) announced the
The following are the guidance documents that will address gene therapies:
Source:






